These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 25783861)

  • 21. Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T cells.
    Stärck L; Popp K; Pircher H; Uckert W
    J Immunol; 2014 Jan; 192(1):206-13. PubMed ID: 24293634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
    Stancovski I; Schindler DG; Waks T; Yarden Y; Sela M; Eshhar Z
    J Immunol; 1993 Dec; 151(11):6577-82. PubMed ID: 7902379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical development of T cell receptor gene therapy.
    Bendle GM; Haanen JB; Schumacher TN
    Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
    Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
    Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic engineering of T cells in leukemia and lymphoma.
    Kochenderfer JN
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):190-2. PubMed ID: 24927269
    [No Abstract]   [Full Text] [Related]  

  • 28. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer.
    Duong CP; Westwood JA; Berry LJ; Darcy PK; Kershaw MH
    Immunotherapy; 2011 Jan; 3(1):33-48. PubMed ID: 21174556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors.
    Gladow M; Uckert W; Blankenstein T
    Eur J Immunol; 2004 Jul; 34(7):1882-91. PubMed ID: 15214036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adoptive immunotherapy using gene-modified T cells to express target-specific receptors against hematological malignancy].
    Fujiwara H
    Rinsho Ketsueki; 2014 Oct; 55(10):2162-74. PubMed ID: 25297783
    [No Abstract]   [Full Text] [Related]  

  • 31. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.
    Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C
    Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-cell sensitivity: a microRNA regulates the sensitivity of the T-cell receptor.
    Laufer TM
    Immunol Cell Biol; 2007 Jul; 85(5):346-7. PubMed ID: 17549074
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunotherapy for glioblastoma: a long and winding road.
    Weller M
    Neuro Oncol; 2010 Apr; 12(4):319. PubMed ID: 20308309
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunotherapy highlights from the 2011 meeting of the American Society of Hematology.
    Hanley PJ; Bollard CM
    Expert Rev Hematol; 2012 Apr; 5(2):145-7. PubMed ID: 22475282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The T cell receptor family is growing.
    Marx JL
    Science; 1987 Jun; 236(4806):1187-8. PubMed ID: 3495883
    [No Abstract]   [Full Text] [Related]  

  • 36. CAR T-cells: an exciting frontier in cancer therapy.
    The Lancet
    Lancet; 2017 Sep; 390(10099):1006. PubMed ID: 28901922
    [No Abstract]   [Full Text] [Related]  

  • 37. First sighting of the elusive T cell antigen receptor.
    Lanier LL
    J Immunol; 2005 Feb; 174(3):1143. PubMed ID: 15661865
    [No Abstract]   [Full Text] [Related]  

  • 38. UK Early Access to Medicines Scheme.
    Burki TK
    Lancet Oncol; 2014 Nov; 15(12):e531. PubMed ID: 25602103
    [No Abstract]   [Full Text] [Related]  

  • 39. Synthetic biology: Reframing cell therapy for cancer.
    Dolberg TB; Donahue PS; Leonard JN
    Nat Chem Biol; 2018 Feb; 14(3):204-205. PubMed ID: 29443984
    [No Abstract]   [Full Text] [Related]  

  • 40. Harnessing naturally occurring mutations for T-cell therapy: a potential new avenue to enhance treatment efficacy.
    Hiltensperger M; Ruland J; Schober K
    Signal Transduct Target Ther; 2024 Apr; 9(1):117. PubMed ID: 38688914
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.